Improved Quality of Life of Patients With Sickle Cell Disease after Allogeneic Stem Cell Transplant: Another Indication for Transplant
Hematology/Oncology and Stem Cell Therapy · 2024
DOI: 10.56875/2589-0646.1107 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hematology/Oncology and Stem Cell Therapy, 2024. Verfasst von Bader A Aljaafri und 10 weiteren Autor:innen. Beteiligte Einrichtung: College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Hemoglobinopathies, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
Background
Sickle cell disease (SCD) is frequently inherited worldwide. The severity of SCD ranges from mild to severe, and the disease involves multiple complications, including pulmonary hypertension, stroke, recurrent vasoocclusive crises, end-organ damage, and an increased mortality risk. Allogeneic hematopoietic cell transplantation (HCT) is a potentially curative option for patients with SCD. Objectives of the study: The objective was to assess the quality of life of adolescent and adult patients with SCD receiving HCT pre-and post-transplant.
Methods
An analytical cross-sectional study was conducted. Patients with SCD with at least one year of follow-up after HCT were interviewed to assess their quality of life pre-and post-transplant. This study was conducted at the Transplant Center of King Abdulaziz Medical City, Riyadh. The participants were identified through non-probability consecutive sampling. The FACT-G questionnaire was used to assess the quality of life domains.
Results
Thirty-one patients were included. The median age of the respondents was 32 ± 6.3 years, and 16 were male (51.6%). The most frequent indication for stem cell transplantation (58%) was a vaso-occlusive crisis. The mean FACT-G scores pre- and post-transplantation were 55.2 ± 18.17 and 91 ± 14.58, respectively. The mean number of annual ER visits was significantly reduced from 27.3 pre-transplant to 6.6 post-transplant (P-value = 0.006). Of the respondents, 51.6% experienced no severe complications post-transplantation, and most (93.5%) reported improved quality of life.
Conclusion
HCT significantly improved the quality of life of adult patients with SCD, with improvements in most FACT-G score domains. Although it was not measured by the FACT-G, the frequency of ER visits and hospital admissions were reduced significantly post-transplant, reflecting an improvement in the quality of life and a reduction in the cost of therapy for patients with SCD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
- King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.
- King Abdulaziz Medical City, Ministry of National Guard, Health Affairs, Riyadh, Saudi Arabia.
- King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
Zitieren
APA
Aljaafri, B. A., Albawardi, M. F., Alghamdi, A. Y., Altowairgi, K. M., Alhoshan, Y. S., Alahmari, B., Alsadi, H., Ahmed, M., Alnahdi, M., Aljubour, Z., & Alzahrani, M. (2024). Improved Quality of Life of Patients With Sickle Cell Disease after Allogeneic Stem Cell Transplant: Another Indication for Transplant. Hematology/Oncology and Stem Cell Therapy. https://doi.org/10.56875/2589-0646.1107
Vancouver
Aljaafri BA, Albawardi MF, Alghamdi AY, Altowairgi KM, Alhoshan YS, Alahmari B, et al. Improved Quality of Life of Patients With Sickle Cell Disease after Allogeneic Stem Cell Transplant: Another Indication for Transplant. Hematology/Oncology and Stem Cell Therapy. 2024. doi:10.56875/2589-0646.1107
BibTeX
@article{Aljaafri2024,
author = {Aljaafri, Bader A and Albawardi, Mohammad F and Alghamdi, Abdulaziz Y and Altowairgi, Khaled M and Alhoshan, Yazeed S and Alahmari, Bader and Alsadi, Husam and Ahmed, Mazin and Alnahdi, Mohammed and Aljubour, Zied and Alzahrani, Mohsen},
title = {Improved Quality of Life of Patients With Sickle Cell Disease after Allogeneic Stem Cell Transplant: Another Indication for Transplant},
journal = {Hematology/Oncology and Stem Cell Therapy},
year = {2024},
doi = {10.56875/2589-0646.1107}
}
EUVIMED